Edesa Biotech Inc Financials

EDSA

Source SEC Filings (10-K/10-Q) Updated Feb 13, 2026 Currency USD FYE September

This page shows Edesa Biotech Inc (EDSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Edesa Biotech Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.02x

For every $1 of reported earnings, Edesa Biotech Inc generates $1.02 in operating cash flow (-$7.3M OCF vs -$7.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$7.8M

YoY-14.1%

Edesa Biotech Inc's EBITDA was -$7.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.1% from the prior year.

Net Income

-$7.2M

YoY-16.5%

Edesa Biotech Inc reported -$7.2M in net income in fiscal year 2025. This represents a decrease of 16.5% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$10.8M

YoY+980.0%

5Y CAGR+8.4%

10Y CAGR+2.1%

Edesa Biotech Inc held $10.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+119.9%

Edesa Biotech Inc had 7M shares outstanding in fiscal year 2025. This represents an increase of 119.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-57.7%

YoY+253.7pp

5Y CAGR+38.3pp

10Y CAGR+22.9pp

Edesa Biotech Inc's ROE was -57.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 253.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$3.7M

YoY+27.3%

5Y CAGR+2.0%

10Y CAGR+4.1%

Edesa Biotech Inc invested $3.7M in research and development in fiscal year 2025. This represents an increase of 27.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

EDSA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	$0-100.0%	$329K
Cost of Revenue	N/A	N/A	N/A	N/A	$0-100.0%	$18K
Gross Profit	N/A	N/A	N/A	N/A	$0-100.0%	$311K
R&D Expenses	$3.7M+27.3%	$2.9M-39.9%	$4.8M-64.0%	$13.3M-25.7%	$17.9M+439.0%	$3.3M
SG&A Expenses	$4.2M+2.7%	$4.1M-6.7%	$4.4M-12.1%	$5.0M-12.2%	$5.7M+69.5%	$3.4M
Operating Income	-$7.9M-12.8%	-$7.0M+23.9%	-$9.2M+49.8%	-$18.4M+22.4%	-$23.7M-270.0%	-$6.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$8000.0%	$8000.0%	$8000.0%	$8000.0%	$8000.0%	$800
Net Income	-$7.2M-16.5%	-$6.2M+26.3%	-$8.4M+52.3%	-$17.5M-31.5%	-$13.3M-109.7%	-$6.4M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.1M0.0%	$1.1M	N/A	$939K+93.9%	$484K-52.5%	$1.0M	N/A	$897K
SG&A Expenses	$1.2M0.0%	$1.2M	N/A	$965K-16.4%	$1.2M+31.4%	$879K	N/A	$1.0M
Operating Income	$2.3M+200.0%	-$2.3M	N/A	-$1.9M-16.2%	-$1.6M+13.7%	-$1.9M	N/A	-$1.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	$0-100.0%	$800	N/A	N/A	$0
Net Income	$2.2M+200.0%	-$2.2M	N/A	-$1.7M-10.0%	-$1.6M+1.7%	-$1.6M	N/A	-$1.7M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

EDSA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$13.5M+254.8%	$3.8M-57.1%	$8.9M-23.2%	$11.6M-20.6%	$14.6M+35.5%	$10.8M
Current Assets	$11.5M+587.1%	$1.7M-74.0%	$6.4M-29.2%	$9.1M-24.8%	$12.1M+49.2%	$8.1M
Cash & Equivalents	$10.8M+980.0%	$1.0M-81.5%	$5.4M-23.8%	$7.1M-9.5%	$7.8M+8.7%	$7.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.1M-41.2%	$1.8M-0.5%	$1.8M-15.7%	$2.2M+43.1%	$1.5M-63.1%	$4.1M
Current Liabilities	$1.1M-41.2%	$1.8M+0.6%	$1.8M-14.9%	$2.1M+46.8%	$1.5M-4.7%	$1.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$12.5M+528.5%	$2.0M-71.9%	$7.0M-24.9%	$9.4M-28.1%	$13.1M+96.9%	$6.6M
Retained Earnings	-$65.9M-12.5%	-$58.6M-11.8%	-$52.4M-19.0%	-$44.0M-66.2%	-$26.5M-101.7%	-$13.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$14.7M0.0%	$14.7M+8.7%	$13.5M-8.6%	$14.8M-10.0%	$16.5M+295.1%	$4.2M+9.2%	$3.8M-27.0%	$5.2M
Current Assets	$12.7M0.0%	$12.7M+10.5%	$11.5M-9.8%	$12.8M-11.3%	$14.4M+594.4%	$2.1M+23.7%	$1.7M-45.0%	$3.0M
Cash & Equivalents	$12-100.0%	$12.1M+12.0%	$10.8M-12.9%	$12.4M-10.8%	$13.9M+768.8%	$1.6M+60.0%	$1.0M-51.0%	$2.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$756K0.0%	$756K-29.9%	$1.1M+60.3%	$673K-26.5%	$915K-51.9%	$1.9M+3.7%	$1.8M-22.4%	$2.4M
Current Liabilities	$756K0.0%	$756K-29.9%	$1.1M+60.3%	$673K-26.5%	$915K-51.9%	$1.9M+3.7%	$1.8M-22.4%	$2.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$14.0M0.0%	$14.0M+12.1%	$12.5M-11.9%	$14.1M-9.1%	$15.5M+586.4%	$2.3M+14.3%	$2.0M-30.9%	$2.9M
Retained Earnings	$68.2M+200.0%	-$68.2M-3.5%	-$65.9M-3.6%	-$63.6M-2.9%	-$61.9M-2.7%	-$60.2M-2.8%	-$58.6M-1.7%	-$57.6M

EDSA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$7.3M-49.7%	-$4.9M+26.3%	-$6.6M+46.0%	-$12.3M+10.1%	-$13.7M-174.0%	-$5.0M
Capital Expenditures	N/A	N/A	$0-100.0%	$6K-8.0%	$6K+26.6%	$5K
Free Cash Flow	N/A	N/A	-$6.6M+46.0%	-$12.3M+10.1%	-$13.7M-173.9%	-$5.0M
Investing Cash Flow	N/A	N/A	$0+100.0%	-$6K+8.0%	-$6K-132.2%	$19K
Financing Cash Flow	$17.0M+2776.7%	$592K-87.7%	$4.8M-58.5%	$11.6M-18.0%	$14.2M+99.8%	$7.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$2.1M+200.0%	-$2.1M-21.3%	-$1.7M-1.2%	-$1.7M+28.6%	-$2.4M-57.1%	-$1.5M-56.9%	-$967K-12.9%	-$856K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$3.4M0.0%	$3.4M+1699.3%	$186K	$0-100.0%	$14.8M+613.1%	$2.1M+6689.9%	-$31K-129.6%	$106K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

EDSA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	94.7%
Operating Margin	N/A	N/A	N/A	N/A	N/A	-1946.7%
Net Margin	N/A	N/A	N/A	N/A	N/A	-1935.3%
Return on Equity	-57.7%+253.7pp	-311.4%-192.6pp	-118.8%+68.1pp	-186.9%-84.7pp	-102.2%-6.2pp	-96.0%
Return on Assets	-53.1%+108.7pp	-161.8%-67.6pp	-94.2%+57.4pp	-151.6%-60.1pp	-91.5%-32.4pp	-59.1%
Current Ratio	10.67+9.8	0.91-2.6	3.53-0.7	4.25-4.0	8.29+3.0	5.30
Debt-to-Equity	0.09-0.8	0.93+0.7	0.26+0.0	0.23+0.1	0.12-0.5	0.62
FCF Margin	N/A	N/A	N/A	N/A	N/A	-1518.0%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	16.1%+32.2pp	-16.1%	N/A	-12.4%-2.1pp	-10.2%+61.2pp	-71.4%	N/A	-58.2%
Return on Assets	15.3%+30.6pp	-15.3%	N/A	-11.8%-2.2pp	-9.7%+29.2pp	-38.8%	N/A	-31.9%
Current Ratio	16.820.0	16.82+6.1	10.67-8.3	18.97+3.2	15.73+14.6	1.09+0.2	0.91-0.4	1.29
Debt-to-Equity	0.050.0	0.05-0.0	0.09+0.0	0.05-0.0	0.06-0.8	0.84-0.1	0.93+0.1	0.82
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

$51.9M

$9.6M

$187.4M

$6.4M

$31.3M

Frequently Asked Questions

Is Edesa Biotech Inc profitable?

No, Edesa Biotech Inc (EDSA) reported a net income of -$7.2M in fiscal year 2025.

What is Edesa Biotech Inc's EBITDA?

Edesa Biotech Inc (EDSA) had EBITDA of -$7.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Edesa Biotech Inc's return on equity (ROE)?

Edesa Biotech Inc (EDSA) has a return on equity of -57.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Edesa Biotech Inc's operating cash flow?

Edesa Biotech Inc (EDSA) generated -$7.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Edesa Biotech Inc's total assets?

Edesa Biotech Inc (EDSA) had $13.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Edesa Biotech Inc spend on research and development?

Edesa Biotech Inc (EDSA) invested $3.7M in research and development during fiscal year 2025.

How many shares does Edesa Biotech Inc have outstanding?

Edesa Biotech Inc (EDSA) had 7M shares outstanding as of fiscal year 2025.

What is Edesa Biotech Inc's current ratio?

Edesa Biotech Inc (EDSA) had a current ratio of 10.67 as of fiscal year 2025, which is generally considered healthy.

What is Edesa Biotech Inc's debt-to-equity ratio?

Edesa Biotech Inc (EDSA) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Edesa Biotech Inc's return on assets (ROA)?

Edesa Biotech Inc (EDSA) had a return on assets of -53.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Edesa Biotech Inc's cash runway?

Based on fiscal year 2025 data, Edesa Biotech Inc (EDSA) had $10.8M in cash against an annual operating cash burn of $7.3M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Edesa Biotech Inc's Piotroski F-Score?

Edesa Biotech Inc (EDSA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Edesa Biotech Inc's earnings high quality?

Edesa Biotech Inc (EDSA) has an earnings quality ratio of 1.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.